Income Taxes (Details Narrative) - USD ($)	Jul. 31, 2018	Jul. 31, 2017
Pretax losses arising from domestic operations	$ 35,948,698	$ (76,823,599)
Pretax losses arising from foreign operations	(150,394)	$ (869,116)
Generex Biotechnology Corporation
NOL carryforwards, expiring through 2036	199,000,000
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2036	35,400,000
Antigen Express, Inc
NOL carryforwards, expiring through 2036	$ 36,700,000

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 25
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115928272&loc=d3e28680-109314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant